Perugia, Italy - Promising phase 2 results with the new oral direct factor Xa inhibitor anticoagulant rivaroxaban (Bayer) in the treatment of patients with deep vein thrombosis (DVT) have been ...
MedPage Today on MSN
Apixaban snags a win in head-to-head trial of direct oral anticoagulants
Favorable safety shown in secondary prevention for acute venous thromboembolism ...
Apixaban halved the risk for bleeding compared with rivaroxaban in the treatment of acute venous thromboembolism in the ...
Apixaban conferred lower bleeding risk during a 3-month period compared with rivaroxaban in patients with acute venous thromboembolism, researchers reported.Despite higher medication adherence to ...
WASHINGTON -- Continuing use of rivaroxaban (Xarelto) at either 20 mg or 10 mg dose appears to reduce the risk of recurrent venous thromboembolism without increasing the risk for bleeding. "This is a ...
Please provide your email address to receive an email when new articles are posted on . The use of a fixed-dose of rivaroxaban was safe and effective and resulted in an 82% relative risk reduction in ...
LOS ANGELES, CA—Another real-world study has suggested that there may be differences among the non-vitamin K antagonist oral anticoagulants (NOACs) in terms of the risk of major bleeding. Among ...
Rivaroxaban shows superiority to standard therapy in net clinical benefit, a secondary endpoint of the study / Rivaroxaban well tolerated in this long-term trial / Full data set to be presented at Hot ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results